These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28853306)

  • 1. Aftermarket Performance of Health Care and Biopharmaceutical IPOs: Evidence From ASEAN Countries.
    Komenkul K; Kiranand S
    Inquiry; 2017 Jan; 54():46958017727105. PubMed ID: 28853306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in biopharmaceutical IPOS: 1996-2005.
    Williams DR; Young CC
    J Health Care Finance; 2006; 33(2):39-54. PubMed ID: 19175239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An empirical analysis of health care IPOs and SEOs.
    Brau JC; Holloway JM
    J Health Care Finance; 2009; 35(4):42-63. PubMed ID: 20515009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financing development stage biotechnology companies: RMs vs. IPOs.
    Ahn MJ; Couch RB; Wu W
    J Health Care Finance; 2011; 38(1):32-54. PubMed ID: 22043645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotech's wellspring: the health of private biotech in 2012.
    Huggett B
    Nat Biotechnol; 2013 May; 31(5):396-403. PubMed ID: 23657390
    [No Abstract]   [Full Text] [Related]  

  • 6. 1999 health care IPOs.
    Brustad C; Serb C
    Hosp Health Netw; 2000 Jan; 74(1):41, 43-6. PubMed ID: 11387747
    [No Abstract]   [Full Text] [Related]  

  • 7. IPOs break $1 billion in Q2.
    Lawrence S
    Nat Biotechnol; 2007 Aug; 25(8):833. PubMed ID: 17687349
    [No Abstract]   [Full Text] [Related]  

  • 8. The aftermarket performance of initial public offerings: New evidence from an emerging market.
    Rathnayake DN; Zhang Z; Yang B; Louembé PA
    PLoS One; 2022; 17(8):e0272092. PubMed ID: 35994480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IPOs: the narrow window closes?
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641
    [No Abstract]   [Full Text] [Related]  

  • 10. The epidemiology of COVID-19 in ten Southeast Asian countries.
    Rampal S; Rampal L; Jayaraj VJ; Pramanick A; Choolani M; Liew BS; Gosavi A; Arj-Ong Vallibhakara S
    Med J Malaysia; 2021 Nov; 76(6):783-791. PubMed ID: 34806661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies.
    Hwang TJ
    PLoS One; 2013; 8(8):e71966. PubMed ID: 23951273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inherent risks associated with newly traded biopharmaceutical firms.
    Williams DR; Spaulding TJ
    Drug Discov Today; 2018 Sep; 23(9):1680-1688. PubMed ID: 29936246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aftermarket performance of initial public offerings for health care firms.
    Hughes DW; Reinhart WJ
    J Ambul Care Mark; 1992; 5(1):185-96. PubMed ID: 10122751
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 15. Going strong, going public. Despite spate of chronic problems and calls for reform, healthcare initial public offerings demonstrate fiscal health.
    Zigmond J
    Mod Healthc; 2007 Dec 24-31; 37(51):6-7, 16, 1. PubMed ID: 18220122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 17. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 18. Do governance, equity characteristics, and venture capital nvolvement affect long-term wealth creation in U.S. health care and biotechnology IPOs?
    Williams DR; Duncan WJ; Ginter PM; Shewchuk RM
    J Health Care Finance; 2006; 33(1):54-71. PubMed ID: 21110493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASEAN.
    United States. Department of State. Bureau of Public Affairs
    Backgr Notes Ser; 1989 Mar; ():1-9. PubMed ID: 12177994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Just how good an investment is the biopharmaceutical sector?
    Thakor RT; Anaya N; Zhang Y; Vilanilam C; Siah KW; Wong CH; Lo AW
    Nat Biotechnol; 2017 Dec; 35(12):1149-1157. PubMed ID: 29220034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.